webinar series
The Breakthrough of Hypertrophic Cardiomyopathy Treatment
Learning Objectives
✅1. Understand HCM pathophysiology and pharmacologic targets
✅2. Review standard therapies and emerging myosin inhibitors
✅3. Apply clinical trial data to treatment decisions
✅4. Identify patients suited for disease-specific therapies
✅5. Recognize pharmacist roles in monitoring and drug management
✅6. Integrate pharmacokinetics/dynamics into therapeutic plans
Who Should Attend
Ideal for cardiologists, internists, GPs, clinical pharmacists, and pharmacotherapy specialists involved in HCM care. Stay current with evolving treatment strategies and enhance your role in delivering evidence-based, multidisciplinary care.
This session also serves as an important platform for pharmacists to expand their role in therapeutic optimization, medication monitoring, and patient education, particularly as more complex and targeted agents become part of clinical practice.
Meet Our International Expert Panel
Dr Craig Beavers (USA) - Moderator
Dr Bassam Atallah (UAE) - Speaker
Ms. Low Peik Ching (Singapore) - Clinical Cases Presenter
Dr Vebiona Kartini Prima Putri (Indonesia) - Panelist
Prof. Kaoru Dohi (Japan) - Panelist
Performed by:
Moderator
Craig Beavers
Speaker
Bassam Atallah
Panelist
Vebiona Kartini Prima Putri
Panelist
Dohi Karou
Clinical Cases Presenter
Low Peik Ching
restricted content
ISCP Members Only
Access to the e-Learning and Experts sections is available to ISCP Members only. Already a Member? Log in Not yet a Member? Visit our Registration page for details of how to join the ISCP and learn more about the benefits of being a part.